Bio Reports
NG-350A combined with chemoradiotherapy demonstrated promising efficacy and a favorable safety profile Composite response rate of 50 percent observed ac...
April 21, 2026 | News
First-in-human study of EPI-326 will evaluate the company’s lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to ...
April 21, 2026 | News
SYNTHBODY™ introduces a new class of “smart drugs”: protein therapeutics with built-in, multi-layered logic gates that actively chang...
April 20, 2026 | News
PFAS analysis has moved from a specialist capability to a core requirement for environmental control and testing laboratories because regulatory values are...
April 21, 2026 | News
NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes Singapore is stren...
April 13, 2026 | News
By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, impr...
April 08, 2026 | News
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases Color...
April 03, 2026 | News
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A signifi...
March 30, 2026 | News
BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing BrightGene Bio-Medical Technology C...
March 26, 2026 | News
CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS Celosia Therapeutics, an Australian biotech company developing advanced gen...
March 25, 2026 | News
Alphamab Oncology announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN02...
March 25, 2026 | News
Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase...
March 25, 2026 | News
Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung can...
March 25, 2026 | News
Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...
March 23, 2026 | News
Most Read
Bio Jobs
News
Editor Picks